You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSalsalate
Accession NumberDB01399
TypeSmall Molecule
GroupsApproved
DescriptionSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Structure
Thumb
Synonyms
2-Carboxyphenyl salicylate
Disalcid
Disalicylic acid
Disalicylsaeure
O-Salicylcylsalicylsaeure
O-Salicylsalicylic acid
Salicylic acid bimolecular ester
Salicyloxysalicylic acid
Salicyloylsalicylic acid
salicylsalicylic acid
Salsalato
Salsalatum
Sasapyrin
Sasapyrine
Sasapyrinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disalcid - Tab 500mgtablet500 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-10-012002-07-09Canada
Disalcid - Tab 750mgtablet750 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-06-012002-07-09Canada
Disalcid Tab 500mgtablet500 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Disalcid Tab 750mgtablet750 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disalcidtablet500 mg/1oralAvion Pharmaceuticals, Llc2014-09-18Not applicableUs
Disalcidtablet750 mg/1oralAvion Pharmaceuticals, Llc2014-09-18Not applicableUs
Salsalatetablet500 mg/1oralECI Pharmaceuticals, LLC2014-10-01Not applicableUs
Salsalatetablet500 mg/1oralAcella Pharmaceuticals, LLC2011-05-16Not applicableUs
Salsalatetablet750 mg/1oralCarilion Materials Management2010-09-24Not applicableUs
Salsalatetablet750 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-09-24Not applicableUs
Salsalatetablet500 mg/1oralMajor Pharmaceuticals1998-08-03Not applicableUs
Salsalatetablet750 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.1995-04-01Not applicableUs
Salsalatetablet750 mg/1oralA S Medication Solutions Llc2010-09-24Not applicableUs
Salsalatetablet, film coated500 mg/1oralNationwide Laboratories, LLC2011-08-19Not applicableUs
Salsalatetablet, film coated750 mg/1oralBoca Pharmacal, Inc.2012-01-162015-12-29Us
Salsalatetablet750 mg/1oralAv Pak2015-02-18Not applicableUs
Salsalatetablet500 mg/1oralAmneal Pharmaceuticals2010-09-24Not applicableUs
Salsalatetablet750 mg/1oralAcella Pharmaceuticals, LLC2011-05-16Not applicableUs
Salsalatetablet750 mg/1oralECI Pharmaceuticals, LLC2014-10-01Not applicableUs
Salsalatetablet750 mg/1oralMajor Pharmaceuticals2004-01-29Not applicableUs
Salsalatetablet500 mg/1oralClinical Solutions Wholesale2010-09-24Not applicableUs
Salsalatetablet500 mg/1oralAv Pak2014-11-18Not applicableUs
Salsalatetablet500 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
Salsalatetablet, film coated750 mg/1oralNationwide Laboratories, LLC2011-08-19Not applicableUs
Salsalatetablet, film coated500 mg/1oral3 T Federal Solutions Llc2012-01-16Not applicableUs
Salsalatetablet750 mg/1oralAmneal Pharmaceuticals2010-09-24Not applicableUs
Salsalatetablet500 mg/1oralAv Kare, Inc.2013-05-172016-02-03Us
Salsalatetablet500 mg/1oralLibertas Pharma, Inc.2011-05-22Not applicableUs
Salsalatetablet750 mg/1oralAv Pak2014-11-18Not applicableUs
Salsalatetablet, film coated500 mg/1oralMarlex Pharmaceuticals Inc2007-04-01Not applicableUs
Salsalatetablet750 mg/1oralClinical Solutions Wholesale2010-09-24Not applicableUs
Salsalatetablet750 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
Salsalatetablet750 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-16Not applicableUs
Salsalatetablet, film coated750 mg/1oral3 T Federal Solutions Llc2012-01-16Not applicableUs
Salsalatetablet750 mg/1oralRebel Distributors Corp1995-04-01Not applicableUs
Salsalatetablet500 mg/1oralCarilion Materials Management2010-09-24Not applicableUs
Salsalatetablet750 mg/1oralLibertas Pharma, Inc.2011-05-22Not applicableUs
Salsalatetablet750 mg/1oralAv Kare, Inc.2013-05-172016-02-03Us
Salsalatetablet, film coated500 mg/1oralBoca Pharmacal, Inc.2012-01-162015-12-29Us
Salsalatetablet500 mg/1oralAv Pak2015-02-18Not applicableUs
Salsalatetablet, film coated750 mg/1oralMarlex Pharmaceuticals Inc2007-04-01Not applicableUs
Salsalatetablet750 mg/1oralbryant ranch prepack1995-04-01Not applicableUs
Salsalatetablet500 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.1995-04-01Not applicableUs
Salsalatetablet750 mg/1oralAphena Pharma Solutions Tennessee, Inc.2011-05-22Not applicableUs
Salsalate Rxtablet, film coated500 mg/1oralAnda Pharm Llc2015-01-01Not applicableUs
Salsalate Rxtablet, film coated750 mg/1oralAnda Pharm Llc2015-01-01Not applicableUs
International Brands
NameCompany
DisalcidNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV9MO595C9I
CAS number552-94-3
WeightAverage: 258.2262
Monoisotopic: 258.05282343
Chemical FormulaC14H10O5
InChI KeyInChIKey=WVYADZUPLLSGPU-UHFFFAOYSA-N
InChI
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
IUPAC Name
2-(2-hydroxybenzoyloxy)benzoic acid
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassDepsides and depsidones
Sub ClassNot Available
Direct ParentDepsides and depsidones
Alternative Parents
Substituents
  • Depside backbone
  • Salicylic acid or derivatives
  • Phenol ester
  • Benzoate ester
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Carboxylic acid ester
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.
PharmacodynamicsSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.
Mechanism of actionThe mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.
Related Articles
AbsorptionSalsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.
Volume of distributionNot Available
Protein bindingSalicylate: 90-95% bound at plasma salicylate concentrations <100 mcg/mL; 70-85% bound at concentrations of 100-400 mcg/mL; 25-60% bound at concentrations >400 mcg/mL.
Metabolism

Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body.

Route of eliminationNot Available
Half lifeThe parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
ClearanceNot Available
ToxicityDeath has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Salsalate Action PathwayDrug actionSMP00707
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9161
Blood Brain Barrier+0.8946
Caco-2 permeable+0.5186
P-glycoprotein substrateNon-substrate0.6391
P-glycoprotein inhibitor INon-inhibitor0.8819
P-glycoprotein inhibitor IINon-inhibitor0.9074
Renal organic cation transporterNon-inhibitor0.8788
CYP450 2C9 substrateNon-substrate0.7946
CYP450 2D6 substrateNon-substrate0.9353
CYP450 3A4 substrateNon-substrate0.7281
CYP450 1A2 substrateNon-inhibitor0.7887
CYP450 2C9 inhibitorNon-inhibitor0.5411
CYP450 2D6 inhibitorNon-inhibitor0.9409
CYP450 2C19 inhibitorNon-inhibitor0.8028
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8116
Ames testNon AMES toxic0.9731
CarcinogenicityNon-carcinogens0.8579
BiodegradationReady biodegradable0.5723
Rat acute toxicity2.4607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9607
hERG inhibition (predictor II)Non-inhibitor0.9403
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
Tabletoral750 mg
Tabletoral500 mg/1
Tabletoral750 mg/1
Tablet, film coatedoral500 mg/1
Tablet, film coatedoral750 mg/1
Prices
Unit descriptionCostUnit
Salsalate powder16.8USD g
Salsalate 750 mg tablet0.55USD tablet
Salflex-750 tablet0.5USD tablet
Salflex-500 tablet0.37USD tablet
Salsalate 500 mg tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.246 mg/mLALOGPS
logP3.44ALOGPS
logP3.64ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.4ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability24.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02BA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabSalsalate may increase the anticoagulant activities of Abciximab.
AcebutololSalsalate may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Salsalate is combined with Aceclofenac.
AcenocoumarolSalsalate may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salsalate.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salsalate.
Alendronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.
AliskirenSalsalate may decrease the antihypertensive activities of Aliskiren.
AlprenololSalsalate may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salsalate.
AmikacinSalsalate may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideSalsalate may decrease the antihypertensive activities of Amiloride.
AncrodSalsalate may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.
Antithrombin III humanSalsalate may increase the anticoagulant activities of Antithrombin III human.
ApixabanSalsalate may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Salsalate is combined with Apremilast.
ArdeparinSalsalate may increase the anticoagulant activities of Ardeparin.
ArgatrobanSalsalate may increase the anticoagulant activities of Argatroban.
ArotinololSalsalate may decrease the antihypertensive activities of Arotinolol.
AtenololSalsalate may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salsalate.
BalsalazideSalsalate may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Salsalate.
BecaplerminSalsalate may increase the anticoagulant activities of Becaplermin.
BefunololSalsalate may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Salsalate.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.
BenoxaprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Benoxaprofen.
BetaxololSalsalate may decrease the antihypertensive activities of Betaxolol.
BevantololSalsalate may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salsalate.
BisoprololSalsalate may decrease the antihypertensive activities of Bisoprolol.
BivalirudinSalsalate may increase the anticoagulant activities of Bivalirudin.
BopindololSalsalate may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.
BufuralolSalsalate may decrease the antihypertensive activities of Bufuralol.
BumetanideSalsalate may decrease the diuretic activities of Bumetanide.
BupranololSalsalate may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salsalate.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Salsalate.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salsalate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salsalate.
CarteololSalsalate may decrease the antihypertensive activities of Carteolol.
CarvedilolSalsalate may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Salsalate is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salsalate.
CeliprololSalsalate may decrease the antihypertensive activities of Celiprolol.
CertoparinSalsalate may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salsalate.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salsalate.
CholestyramineCholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salsalate.
Citric AcidSalsalate may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Salsalate is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salsalate.
ColesevelamColesevelam can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineSalsalate may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Salsalate is combined with D-Limonene.
Dabigatran etexilateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinSalsalate may increase the anticoagulant activities of Dalteparin.
DanaparoidSalsalate may increase the anticoagulant activities of Danaparoid.
DaunorubicinSalsalate may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Salsalate is combined with Deferasirox.
DesirudinSalsalate may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salsalate.
DextranSalsalate may increase the anticoagulant activities of Dextran.
Dextran 40Salsalate may increase the anticoagulant activities of Dextran 40.
Dextran 70Salsalate may increase the anticoagulant activities of Dextran 70.
Dextran 75Salsalate may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salsalate.
DicoumarolSalsalate may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salsalate.
DihydrostreptomycinSalsalate may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salsalate.
DoxorubicinSalsalate may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneSalsalate may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Droxicam.
Edetic AcidSalsalate may increase the anticoagulant activities of Edetic Acid.
EdoxabanSalsalate may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Salsalate.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salsalate.
EnoxaparinSalsalate may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Salsalate is combined with Epirizole.
EpirubicinSalsalate may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneSalsalate may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.
EsmololSalsalate may decrease the antihypertensive activities of Esmolol.
Etacrynic acidSalsalate may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.
Ethyl biscoumacetateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salsalate.
EtofenamateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Salsalate is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Salsalate is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Salsalate is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salsalate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salsalate.
FlunixinThe risk or severity of adverse effects can be increased when Salsalate is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salsalate.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salsalate.
Fondaparinux sodiumSalsalate may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salsalate.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salsalate.
FramycetinSalsalate may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideSalsalate may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salsalate.
GentamicinSalsalate may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.
HeparinSalsalate may increase the anticoagulant activities of Heparin.
HirulogSalsalate may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Salsalate is combined with HMPL-004.
HydralazineSalsalate may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salsalate.
Hygromycin BSalsalate may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate.
IbuproxamThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Salsalate is combined with Icatibant.
IdarubicinSalsalate may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.
IndenololSalsalate may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.
IndoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.
IsoxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Isoxicam.
KanamycinSalsalate may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salsalate.
LabetalolSalsalate may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salsalate.
LepirudinSalsalate may increase the anticoagulant activities of Lepirudin.
LevobunololSalsalate may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salsalate.
LithiumThe serum concentration of Lithium can be increased when it is combined with Salsalate.
LornoxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.
LoxoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salsalate.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Salsalate.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salsalate.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salsalate.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.
MesalazineSalsalate may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salsalate.
MetamizoleThe risk or severity of adverse effects can be increased when Salsalate is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salsalate.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.
MetipranololSalsalate may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.
MetoprololSalsalate may decrease the antihypertensive activities of Metoprolol.
MetrizamideSalsalate may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salsalate.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Salsalate.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salsalate.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salsalate.
NadololSalsalate may decrease the antihypertensive activities of Nadolol.
NadroparinSalsalate may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salsalate.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salsalate.
NCX 4016The risk or severity of adverse effects can be increased when Salsalate is combined with NCX 4016.
NeomycinSalsalate may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Salsalate is combined with Nepafenac.
NetilmicinSalsalate may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salsalate.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.
OlsalazineSalsalate may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salsalate.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Salsalate is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Salsalate.
OrgoteinThe risk or severity of adverse effects can be increased when Salsalate is combined with Orgotein.
OtamixabanSalsalate may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.
OxprenololSalsalate may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Parecoxib.
ParomomycinSalsalate may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololSalsalate may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Salsalate.
PhenindioneSalsalate may increase the anticoagulant activities of Phenindione.
PhenprocoumonSalsalate may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salsalate.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.
PindololSalsalate may decrease the antihypertensive activities of Pindolol.
PiretanideSalsalate may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.
PlicamycinSalsalate may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salsalate.
PractololSalsalate may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salsalate.
ProbenecidThe serum concentration of Salsalate can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Salsalate is combined with Propacetamol.
PropranololSalsalate may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Salsalate.
Protein CSalsalate may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSalsalate may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Salsalate is combined with PTC299.
PuromycinSalsalate may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Salsalate.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salsalate.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Salsalate.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salsalate.
ResveratrolThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.
ReviparinSalsalate may increase the anticoagulant activities of Reviparin.
RibostamycinSalsalate may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.
RivaroxabanSalsalate may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Salsalate.
SalicylamideThe risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salsalate.
SeratrodastThe risk or severity of adverse effects can be increased when Salsalate is combined with Seratrodast.
SotalolSalsalate may decrease the antihypertensive activities of Sotalol.
SpectinomycinSalsalate may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Salsalate.
SpironolactoneSalsalate may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Salsalate is combined with SRT501.
StreptomycinSalsalate may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinSalsalate may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineSalsalate may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salsalate.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salsalate.
SulodexideSalsalate may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.
TacrolimusSalsalate may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salsalate.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salsalate.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Salsalate.
TenofovirThe risk or severity of adverse effects can be increased when Salsalate is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salsalate.
TepoxalinThe risk or severity of adverse effects can be increased when Salsalate is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Salsalate is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiludronate.
TimololSalsalate may decrease the antihypertensive activities of Timolol.
TobramycinSalsalate may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.
TorasemideSalsalate may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salsalate.
TranilastThe risk or severity of adverse effects can be increased when Salsalate is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.
TriamtereneSalsalate may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salsalate.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Salsalate is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salsalate.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salsalate.
WarfarinSalsalate may increase the anticoagulant activities of Warfarin.
XimelagatranSalsalate may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salsalate.
Zoledronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Salsalate is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Stichtenoth DO, Zeidler H, Frolich JC: [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. Med Klin (Munich). 1998 Jul 15;93(7):407-15. [PubMed:9711054 ]
  2. Schaefer MG, Plowman BK, Morreale AP, Egan M: Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23. [PubMed:12901032 ]
  3. Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32. [PubMed:16808554 ]
  4. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. [PubMed:15242723 ]
  2. Schmidt A, Hescheler J, Offermanns S, Spicher K, Hinsch KD, Klinz FJ, Codina J, Birnbaumer L, Gausepohl H, Frank R, et al.: Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991 Sep 25;266(27):18025-33. [PubMed:1680855 ]
  3. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:05 / Updated on August 17, 2016 12:23